TY - JOUR T1 - Quantifying the social distancing privilege gap: a longitudinal study of smartphone movement JF - medRxiv DO - 10.1101/2020.05.03.20084624 SP - 2020.05.03.20084624 AU - Nabarun Dasgupta AU - Michele Jonsson Funk AU - Allison Lazard AU - Benjamin Eugene White AU - Stephen W. Marshall Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/08/2020.05.03.20084624.abstract N2 - Background In response to the coronavirus pandemic, social distancing became a widely deployed countermeasure in March 2020. We examined whether healthier and wealthier places more successfully implemented social distancing.Methods Mobile device location data were used to quantify declines in movement by county (n=2,633) in the United States of America, comparing April 15–17 (n=65,544,268 traces) to baseline of February 17 - March 7. Negative binomial regression was used to estimate gradients of privilege across eleven healthcare and economic indicators, adjusting for rurality and stay-at-home mandates. External validation used separate venue-specific data from Google Location Services.Findings Counties without stay-at-home orders showed a mobility decline of −52·3% (95% CI: −50·3%, −54·3%), slightly less than the decline in mandated areas (−60·8%; 95% CI: −60·0%, −61·6%). Strong linear gradients in privilege were observed. After adjusting for rurality and stay-at-home orders, counties in the highest quintile of social distancing mobility restriction had: 52% less uninsured, 47% more primary care providers, 29% more exercise space, 27% less food insecurity, 26% less child poverty, 17% higher incomes, 14% less overcrowding, 9·6% more racial segregation, 8·2% less youth, 7·4% more elderly, and 6·2% less influenza vaccination, compared to least social distancing areas.Interpretation Healthier and wealthier counties displayed a social distancing privilege gap, measured via smartphone mobility change. Structural inequities in this key countermeasure will influence immunity, and disease incidence and mortality.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study used only data that were publicly available. https://github.com/opioiddatalab/covid ER -